Emerging studies suggest this peptide, a dual agonist targeting both GLP-1 and GIP , could offer a notable development for obesity treatment. Preliminary human tests have shown substantial https://getretatrutideaustralia.com/blog/retatrutide-weight-loss-revolution-2026